The Finance and Tax Advisory Committee (FTAC) guides the BIA’s policies and initiatives to create a supportive financial environment for UK bioscience companies. The committee is the forum where BIA members can directly input into policy development and interactions with Government on finance and tax matters.
While the BIA had significant success in Budget 2011, Budget 2013 and Budget 2014, especially around R&D tax credits and the introduction of the Patent Box, much work lies ahead.
Priorities for 2018:
- Continue to engage with non-members inside and outside the sector including the finance and investment community, invite a guest speaker to each meeting, and host inaugural Committee Drinks
- Continue to generate ideas and support the BIA in relevant consultations from government and other bodies, including HM Treasury & HMRC
- Implementation of relevant sections of Patient Capital Review will be a key focus. FTAC stand ready to support BIA engagement on implementation of changes to EIS, VCT and Entrepreneurs Relief
- Keep BIA members informed about developments, best practice and their responsibilities, as well as actively seeking member feedback and engagement, and represent the sector at government meetings and forums
Committee Chair: Colin Hailey, Partner, Confluence Tax
For more information contact Dr Martin Turner, Policy and Projects Manager
BioCity Group Limited
BioCity Group specialises in the creation and development of life science businesses. It provides homes and access to high-end equipment, shared services, training, business support and access to investment for new and growing bioscience businesses.
BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders.
Confluence Tax LLP
Confluence Tax LLP specialises in high quality and cost effective tax advice tax advice for early stage technology and life science companies.
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer.
FTI is designed to address the interrelated challenges that can affect an organization’s enterprise value
GE Healthcare UK Ltd
GE is a global infrastructure, finance and media company taking on the world's toughest challenges.
Ingenza Ltd. is an industrial biotechnology company based in Roslin, Edinburgh, UK. The company has a broad customer base within the chemicals, pharmaceuticals, food, feed and fuel industries where it applies its proprietary synthetic biology to manufacture industrial products.
Karus Therapeutics Ltd
Karus is an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer.
Norton Rose Fulbright LLP
Norton Rose Fulbright is a full service, global law firm with over 3800 lawyers based in more than 50 cities internationally.
We are proud of our heritage, but we're firmly focused on becoming the law firm of the future for our clients, and our people.
Oxford BioMedica plc
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.
Pinsent Masons LLP
Pinsent Masons is a full-services law firm with offices across the UK, Europe and Asia offering the very highest level of market intelligence and experience.
ReNeuron Group Plc
ReNeuron are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
Silicon Valley Bank
Silicon Valley Bank provides unique and flexible financial solutions to some of the most innovative and entrepreneurial companies in the world.
Summit (Oxford) Limited
Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need.
Syncona Investment Managment Limited
Syncona Investment Management Limited is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to significantly impact the healthcare market of the future.
Vertex Pharmaceuticals (Europe) Ltd
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Ernst & Young is one of the world's leading business and financial advisers, helping clients to operate efficiently, profitably and successfully. Our UK firm is a multi-discipline professional services organisation providing a wide range of assurance and consulting services to the business and public sectors. We are committed to providing value to our clients and achieving our vision of being recognised as the professional services firm that contributes most to its clients' success.
AstraZeneca is a major contributor to UK science and innovation investment, economic prosperity and to patient health. The UK is home to the organisations global headquarters and major research and development and manufacturing facilities. AstraZeneca invest over £1.3 billion per year in research and development in the UK.
Mereo BioPharma Group
Mereo is a UK-based biopharmaceutical company focused on the development of innovative medicines in rare and specialty areas.
CellCentric is a drug discovery company focused on epigenetics, a major new area for novel small molecule therapeutics. The company is pursuing novel treatments for prostate, breast and amongst other cancers.
GW Pharmaceuticals Plc
GW Pharmaceuticals was founded in 1998 and listed on AIM, a market of the London Stock Exchange, in June 2001. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines, including Sativex® Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications. GW has assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW maintains in-house control over all aspects of the cannabinoid product development process - botanical research, extraction technology, formulation into drug delivery technologies, clinical trials and regulatory affairs. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.